A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
Trial details
- Registry ID
- NCT06015841
- Drugs studied
- ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional), ACI-7104.056 at Dose C (optional)
TrialRedline tracks 1 clinical trial sponsored by AC Immune SA: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's DiseaseNCT06015841 | ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional), ACI-7104.056 at Dose C (optional) | Active not recruiting | 2028-06Estimated |
Names as written in the registry records.
NCT06015841 · AC Immune SA
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, or unlikely, possibly, probably or definitely related) Time frame: From Screening (ICF signature) to Week 100 Measure: Number of participants with abnormal MRI results Time frame: From Baseline to Week 100 Measure: Number of participants with clinically significant changes in physical and neurological examination results Time frame: From Baseline to Week 74 Measure: Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS) Time frame: From Baseline to Week 100 Measure: Measurement of levels of specific antibodies against a-synuclein present in serum generated by ACI-7104.056 Time frame: From Baseline to Week 100. After: Measure: Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, or unlikely, possibly, probably or definitely related) Time frame: From Screening (ICF signature) to Week 100 in study part 1 and 2, and from Rescreening (ICF signature) to Week 78 in the extension phase Measure: Number of participants with abnormal MRI results Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Number of participants with clinically significant changes in physical and neurological examination results Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS) Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Measurement of levels of specific antibodies against a-synuclein present in serum generated by ACI-7104.056 Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase.
Before: Jan 2028. After: Jun 2028.